The results from a clinical study that we conducted indicated that the AMH levels of premenopausal breast cancer patients over 35 years old were reduced after CTX-based chemotherapy, and the level of serum AMH before chemotherapy can be used as a predictor of menstrual recovery after chemotherapy (Li et al. 2020). The gene discussed is AMH; the disease is breast carcinoma.